• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cannabis Stock Gainers And Losers From March 7, 2024

    3/7/24 4:30:05 PM ET
    $CARA
    $CRBP
    $EAST
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CARA alert in real time by email

    GAINERS:

    • AusCann Group Holdings (OTC:ACNNF) shares closed up 766.67% at $0.03
    • Elixinol Wellness (OTC:ELLXF) shares closed up 75.49% at $0.01
    • Rocky Mountain High (OTC:RMHB) shares closed up 66.67% at $0.01
    • Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 20.07% at $40.32
    • Nextleaf Solutions (OTC:OILFF) shares closed up 10.31% at $0.11
    • Emeren Group (NYSE:SOL) shares closed up 7.92% at $2.18
    • Psychemedics (NASDAQ:PMD) shares closed up 7.36% at $3.21
    • Cannabix Technologies (OTC:BLOZF) shares closed up 7.01% at $0.17
    • Cara Therapeutics (NASDAQ:CARA) shares closed up 6.05% at $1.05
    • Eastside Distilling (NASDAQ:EAST) shares closed up 4.55% at $1.15
    • Body and Mind (OTC:BMMJ) shares closed up 4.29% at $0.07
    • Auxly Cannabis Group (OTC:CBWTF) shares closed up 4.17% at $0.01

    LOSERS:

    • Global Hemp Group (OTC:GBHPF) shares closed down 48.89% at $0.03
    • Item 9 Labs (OTC:INLB) shares closed down 25.00% at $0.00
    • Global Compliance (OTC:FUAPF) shares closed down 18.21% at $0.01
    • Blueberries Medical (OTC:BBRRF) shares closed down 14.67% at $0.01
    • CLS Holdings USA (OTC:CLSH) shares closed down 12.73% at $0.05
    • Target Group (OTC:CBDY) shares closed down 12.48% at $0.00
    • SOL Glb Inv (OTC:SOLCF) shares closed down 9.77% at $0.06
    • 22nd Century Group (NASDAQ:XXII) shares closed down 9.44% at $0.15
    • BioHarvest Sciences (OTC:CNVCF) shares closed down 7.25% at $0.15
    • Charlottes Web Holdings (OTC:CWBHF) shares closed down 6.69% at $0.15
    • Neptune Wellness Solns (NASDAQ:NEPT) shares closed down 5.00% at $0.19
    • Heritage Cannabis Holding (OTC:HERTF) shares closed down 4.46% at $0.01
    • Leafbuyer Techs (OTC:LBUY) shares closed down 3.95% at $0.03
    • Curaleaf Holdings (OTC:CURLF) shares closed down 3.90% at $4.19
    • CV Sciences (OTC:CVSI) shares closed down 3.41% at $0.03
    • Indiva (OTC:NDVAF) shares closed down 3.28% at $0.07

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARA
    $CRBP
    $EAST
    $NEPT

    CompanyDatePrice TargetRatingAnalyst
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2025$28.00Buy
    B. Riley Securities
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    2/28/2025Outperform
    William Blair
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    12/2/2024Overweight
    Piper Sandler
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2024$85.00Outperform
    Wedbush
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/22/2024$80.00Buy
    H.C. Wainwright
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    6/26/2024$85.00Buy
    B. Riley Securities
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $CARA
    $CRBP
    $EAST
    $NEPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

    NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026. 36th Annual Oppenheimer Healthcare Life Sciences Conference Format: Virtual presentation and one-on-one investor meetings Date: February 25, 2026 Presentation Time: 3:20pm Eastern TimeWebcast Link: Click Here About CorbusCorbus Pharmaceuticals Holdings, Inc. is a clinical stage oncolog

    2/12/26 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    22nd Century CEO & Chairman Larry Firestone Provides 2025 Year-in-Review Letter to Stockholders

    MOCKSVILLE, N.C., Jan. 15, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today issued the following letter to stockholders from Lawrence Firestone, the Chief Executive Officer of 22nd Century Group, Inc.:  2025 Year-in-Review Shareholder Letter Dear Shareholders, 2025 was a pivotal year for 22nd Century Group, Inc. as we exited our multi-year restructuring, began advancing our strategic initiatives, strengthened our financial foundation, and reinforced our leadership position in tobacco harm reduction. In a complex regu

    1/15/26 9:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CRBP
    $EAST
    $NEPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Hodgson Ian sold $6,253 worth of shares (847 units at $7.38), decreasing direct ownership by 2% to 51,080 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/18/26 4:32:02 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Moran Sean F. sold $36,588 worth of shares (4,701 units at $7.78), decreasing direct ownership by 5% to 96,694 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/18/26 4:31:03 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Cohen Yuval sold $107,952 worth of shares (13,871 units at $7.78), decreasing direct ownership by 7% to 174,316 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/18/26 4:30:13 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $EAST
    $NEPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN Shah Capital Management bought $29,786 worth of American Depositary Shares (16,853 units at $1.77) (SEC Form 4)

    4 - Emeren Group Ltd (0001417892) (Issuer)

    12/20/24 4:05:29 PM ET
    $SOL
    Semiconductors
    Technology

    Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/17/24 8:29:49 PM ET
    $PMD
    Medical Specialities
    Health Care

    CHAIRMAN Shah Capital Management bought $104,290 worth of American Depositary Shares (58,921 units at $1.77) (SEC Form 4)

    4 - Emeren Group Ltd (0001417892) (Issuer)

    12/16/24 6:39:51 AM ET
    $SOL
    Semiconductors
    Technology

    $CARA
    $CRBP
    $EAST
    $NEPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on Corbus Pharma with a new price target

    B. Riley Securities resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $28.00

    7/30/25 8:22:15 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Corbus Pharma

    William Blair initiated coverage of Corbus Pharma with a rating of Outperform

    2/28/25 7:22:12 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Corbus Pharma

    Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

    12/2/24 9:55:40 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $EAST
    $NEPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $EAST
    $NEPT
    SEC Filings

    View All

    22nd Century Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    2/20/26 4:15:28 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SCHEDULE 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    2/10/26 1:14:49 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    22nd Century Group Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    1/22/26 8:00:48 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CRBP
    $EAST
    $NEPT
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

    CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending d

    12/11/25 7:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

    NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced the Company's plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursday, December 11, 2025. Corbus will host a conference call and live webcast the same day at 8:00 am ET to review and discuss the Phase 1a data. To register for the webcast, click here . A replay will be available on the Corbus website. About CRB-913CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (

    12/10/25 4:01:00 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $EAST
    $NEPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/12/24 5:15:40 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

    SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/6/24 9:18:20 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/5/24 6:04:48 PM ET
    $PMD
    Medical Specialities
    Health Care

    $CARA
    $CRBP
    $EAST
    $NEPT
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Emeren Group Announces North America Management Change and Preliminary Q2 2025 Operating Results

    NORWALK, Conn., July 3, 2025 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE:SOL), a leading global solar project developer, owner, and operator, today announced a leadership transition within its North America operations. Mr. Cameron "Mac" Moore, Executive Vice President - North America, has departed the Company, and Mr. M. Jahangir Alam has been appointed as his successor, effective immediately. About M. Jahangir Alam M. Jahangir Alam is a seasoned leader in the North American renewable energy industry, with nearly three decades of experie

    7/3/25 4:30:00 PM ET
    $SOL
    Semiconductors
    Technology

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care